BusinessCyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker SuppressionBy Nasdaq OMXAug 7, 2017, 11:01 AM UTC
BusinessCyclacel Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment OptionBy Nasdaq OMXJul 21, 2017, 6:00 PM UTC
BusinessCyclacel Announces Pricing of $13.2 Million Underwritten Public OfferingBy Nasdaq OMXJul 19, 2017, 12:30 PM UTC
BusinessCyclacel Pharmaceuticals Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 11, 2017, 8:05 PM UTC
BusinessCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 28, 2017, 8:05 PM UTC
BusinessCyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCIBy Nasdaq OMXMar 7, 2017, 12:00 PM UTC
BusinessCyclacel’s CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer 2016By Nasdaq OMXSep 6, 2016, 11:01 AM UTC
BusinessCyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET InhibitorsBy Nasdaq OMXApr 18, 2016, 1:00 PM UTC
